Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $3.0 million.

  • Prestige Consumer Healthcare's Capital Expenditures rose 9335.89% to $3.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.4 million, marking a year-over-year increase of 1976.42%. This contributed to the annual value of $8.2 million for FY2025, which is 1388.48% down from last year.
  • Per Prestige Consumer Healthcare's latest filing, its Capital Expenditures stood at $3.0 million for Q4 2025, which was up 9335.89% from $2.1 million recorded in Q3 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Capital Expenditures peaked at $4.9 million during Q1 2021, and registered a low of $838000.0 during Q2 2025.
  • Its 5-year average for Capital Expenditures is $2.3 million, with a median of $2.2 million in 2021.
  • As far as peak fluctuations go, Prestige Consumer Healthcare's Capital Expenditures crashed by 6964.48% in 2021, and later soared by 9335.89% in 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Capital Expenditures (Quarter) stood at $2.2 million in 2021, then dropped by 19.11% to $1.8 million in 2022, then increased by 10.7% to $2.0 million in 2023, then fell by 21.54% to $1.6 million in 2024, then skyrocketed by 93.36% to $3.0 million in 2025.
  • Its Capital Expenditures was $3.0 million in Q4 2025, compared to $2.1 million in Q3 2025 and $838000.0 in Q2 2025.